Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-07-31

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

New effective non-surgical treatments are needed for patients whose obesity and type 2 diabetes (T2DM) do not respond to current medical therapies. We propose a randomised controlled trial of Endobarrier, an implantable intestinal device that separates ingested food from contacting the first 60cm of intestine where sited and that mimics some of the clinical effects of bariatric surgery (improved metabolic control with weight loss) with or without continued use of the GLP-1 receptor agonist (GLP-1RA) Liraglutide 1.2mg vs Liraglutide 1.8mg without the device in obese patients with T2DM who remain with suboptimal glycaemic control despite current conventional diabetes treatment, in an NHS setting.

Seventy-two patients with T2DM and obesity (HbA1c≥7.5%, BMI≥35kg/m2) despite previous GLP-1RA therapy will be studied over 24 months and randomised to receive Endobarrier with continued Liraglutide 1.2mg for 12 months; Endobarrier alone for 12 months; or Liraglutide 1.8mg without Endobarrier.

We will investigate potential mechanisms of action and their time course as part of the study by repeated measures of: 1. insulin resistance measures, gut peptides, bile acids; 2. energy intake and nutritional composition; 3. liver fat stores, 4. intestinal inflammation and permeability measures.

The data will inform clinical use of the device and development of new treatments for T2DM and obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

EndoBarrier TM Gastrointestinal Liner Diabetes Trial

NCT02459561

Overweight and Obesity Diabetes

UNKNOWN NA

The Lowering Weight in Severe Obesity by Embolization of the Gastric Artery Trial

NCT03185949

Obesity, Morbid

COMPLETED NA

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

NCT07297238

Short Bowel Syndrome (SBS) Intestinal Failure

NOT_YET_RECRUITING NA

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

NCT02417103

Obesity

TERMINATED PHASE3

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

NCT06734312

Obesity and Obesity-related Medical Conditions Obesity and Overweight Obesity Prevention +3 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Obesity Diabesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liraglutide alone

Liraglutide 1.8mg once daily subcutaneous injection

Group Type ACTIVE_COMPARATOR

Liraglutide

Intervention Type DRUG

Endobarrier alone

Duodenal-jejunal bypass liner (Endobarrier) device implantation without additional GLP-1RA therapy

Group Type EXPERIMENTAL

Duodenal-jejunal bypass liner - Endobarrier device

Intervention Type DEVICE

Endobarrier and Liraglutide

Duodenal-jejunal bypass liner (Endobarrier) device with combined liraglutide 1.2mg once daily subcutaneous injection

Group Type EXPERIMENTAL

Liraglutide

Intervention Type DRUG

Duodenal-jejunal bypass liner - Endobarrier device

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liraglutide

Intervention Type DRUG

Duodenal-jejunal bypass liner - Endobarrier device

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Victoza EC Certificate Full Quality Assurance System: Certificate US08/5323

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 2 diabetes with latest HbA1c ≥7.5% (≥58mmol/mol)
* obesity with latest BMI ≥35 Kg/m2 (≥30 Kg/m2 for those of South Asian origin)
* liraglutide therapy for at least 6 months - HbA1c and weight trend data should be available
* stable weight and HbA1c in preceding 3 months (\<3 Kg reduction in weight and \<0.3% reduction in HbA1c)

Exclusion Criteria

* \<18 years of age
* abnormal intestinal anatomy e.g. Crohn's disease
* contraindication to oesophago-gastroduodenoscopy
* previous bariatric surgery or bowel surgery
* active infection
* anticoagulation therapy which cannot be discontinued/ coagulopathy INR \>1.3
* eGFR \<30
* known portal hypertension
* previous pancreatitis or amylase \> 3 times the upper limit of normal
* uncontrolled cardiovascular disease
* lactating or pregnant females
* patients taking aspirin in whom it should continue (e.g. active ischaemic heart disease or cerebrovascular disease)
* excess anaesthetic risk as identified by the anaesthetist or investigator (e.g. uncontrolled obstructive sleep apnoea)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No